Enzo Biochem, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2941001024
USD
0.70
0.01 (1.66%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Enzo Biochem, Inc. stock-summary
stock-summary
Enzo Biochem, Inc.
Pharmaceuticals & Biotechnology
Enzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company's segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women's health infectious agents, as well as for use in the identification of pathogens for other markets.
Company Coordinates stock-summary
Company Details
60 EXECUTIVE BLVD , FARMINGDALE NY : 11735
stock-summary
Tel: 1 516 7555500
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 9 Schemes (7.53%)

Foreign Institutions

Held by 14 Foreign Institutions (0.79%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Elazar Rabbani
Chairman of the Board, Chief Executive Officer, Secretary
Mr. Dov Perlysky
Lead Independent Director
Ms. Rebecca Fischer
Independent Director
Dr. Mary Tagliaferri
Independent Director
Dr. Ian Walters
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
6 Million
(Quarterly Results - Apr 2025)
Net Profit:
-2 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 37 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

10,873.16%

stock-summary
Debt Equity

-0.82

stock-summary
Return on Equity

-14.89%

stock-summary
Price to Book

0.84